Barclays’s Soleno Therapeutics SLNO Stock Holding History

Barclays’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-28,400	Closed	-$1.92M	–	5642
2025 Q3	$1.92M	Buy	+28,400	New	+$2.11M	﹤0.01%	2919
2025 Q2	–	Sell	-10,000	Closed	-$715K	–	5517
2025 Q1	$715K	Buy	+10,000	New	+$487K	﹤0.01%	3301

Barclays's SLNO Position: Q2 2026 in Review

Barclays sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 54,219 shares — an estimated $1.82M sold.

Barclays first reported a position in SLNO in Q2 2020 and held it in 16 quarters. The position peaked at $11.6M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Barclays reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Barclays sold 54,219 Soleno Therapeutics shares in Q2 2026, an estimated $1.82M.
Barclays first reported a position in Soleno Therapeutics in Q2 2020 and held it in 16 quarters.
Barclays's Soleno Therapeutics position peaked at $11.6M in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.